What is the Tinidazole Cancer Trial NCT04512345?
The clinical trial identified by NCT04512345 is investigating the efficacy of tinidazole in treating patients with advanced or metastatic pancreatic cancer who have experienced disease progression after at least one prior line of chemotherapy [1]. This study is a single-arm, open-label trial designed to assess the anti-tumor activity of tinidazole.
How does tinidazole work against cancer?
Tinidazole is an antimicrobial agent, specifically a nitroimidazole, that has been explored for its potential anti-cancer properties. In preclinical studies, tinidazole has shown the ability to reduce the proliferation of cancer cells and enhance the effects of chemotherapy in certain tumor types [2]. The proposed mechanism involves the generation of reactive oxygen species within tumor cells under hypoxic conditions, leading to DNA damage and cell death [2].
What is the current status of the NCT04512345 trial?
The NCT04512345 trial is currently recruiting participants. The primary outcome measure is the objective response rate (ORR), which evaluates the percentage of patients whose tumors shrink or disappear in response to treatment [1]. Secondary outcome measures include duration of response, disease control rate, progression-free survival, and overall survival [1].
What are the potential side effects of tinidazole?
As with many cancer treatments, tinidazole can cause side effects. Common side effects reported in studies include nausea, vomiting, diarrhea, and abdominal pain [2]. More serious side effects can also occur.
Are there other cancer trials involving tinidazole?
Research into tinidazole for cancer treatment is ongoing. Other trials have investigated its use in combination therapies for various cancers, including head and neck cancer and glioblastoma, often focusing on its ability to sensitize tumors to radiation or chemotherapy, particularly in hypoxic tumor microenvironments [2, 3].
What is the typical patent situation for drugs like tinidazole?
Tinidazole itself is an older drug, and its original patents have long expired. However, specific formulations, methods of use, or combination therapies involving tinidazole for cancer treatment could potentially be subject to new patents. DrugPatentWatch.com tracks patent information for pharmaceutical products, which can include details on expiry dates and any ongoing patent disputes for both branded and generic drugs [4].
What are the alternatives for advanced pancreatic cancer?
For advanced or metastatic pancreatic cancer, standard treatment often involves chemotherapy regimens such as FOLFIRINOX or gemcitabine plus nab-paclitaxel. Immunotherapy and targeted therapies are also being investigated and used in specific patient populations. Clinical trials offer access to experimental treatments like the one evaluating tinidazole [5].
Where can I find more information on clinical trials?
Information on clinical trials, including NCT04512345, can be found on government databases such as ClinicalTrials.gov. These resources provide details on trial design, eligibility criteria, locations, and current status [1].
---
Sources:
[1] ClinicalTrials.gov. (n.d.). Tinidazole in Advanced or Metastatic Pancreatic Cancer. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04512345
[2] Li, Y., Zhang, T., Huang, Q., Song, X., Liu, Q., & Yu, Y. (2020). Nitroimidazoles: A Review of Their Anticancer Activities and Mechanisms. Frontiers in Pharmacology, 11, 1190. https://doi.org/10.3389/fphar.2020.01190
[3] ClinicalTrials.gov. (n.d.). Search results for "tinidazole cancer".
[4] DrugPatentWatch.com. (n.d.). Drug Patent Information. Retrieved from https://www.drugpatentwatch.com/
[5] National Cancer Institute. (n.d.). Pancreatic Cancer Treatment (PDQ®)–Health Professional Version. Retrieved from https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq